Cargando…
MEDB-52. Organoids as preclinical models to improve and personalize disease outcome for sonic hedgehog medulloblastoma
Four main medulloblastoma (MB) molecular subgroups are known, including the sonic hedgehog (SHH) subgroup, which represents ~25% of MB cases. The 5-year overall survival of SHH-MB is ~80%. However, survival between patients is highly diverse and dependent on the driver mutation(s) of the tumor. Pati...
Autores principales: | Odé, Zelda, Maas, Joris, Roosen, Mieke, Stathi, Phylicia, Federico, Aniello, Mack, Norman, Schwalm, Benjamin, Bunt, Jens, Kool, Marcel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164751/ http://dx.doi.org/10.1093/neuonc/noac079.426 |
Ejemplares similares
-
MEDB-57.GNAS inactivation as a driver for sonic hedgehog-activated medulloblastoma
por: Goode, Erin, et al.
Publicado: (2022) -
MEDB-02. The identification and functional characterization of circular RNA Circ_63706 in sonic hedgehog medulloblastomas
por: Pokhrel, Rudramani, et al.
Publicado: (2022) -
MEDB-45. Functional genomics identifies epigenetic regulators as novel therapeutic targets for sonic hedgehog medulloblastoma
por: Tsiami, Foteini, et al.
Publicado: (2022) -
MEDB-41. Identifying a subgroup of patients with early childhood sonic hedgehog-activated medulloblastoma with unfavorable prognosis after treatment with radiation-sparing regimens including intraventricular methotrexate
por: Tonn, Svenja, et al.
Publicado: (2022) -
MEDB-06. Spatial transcriptomic analysis of Sonic Hedgehog Medulloblastoma identifies that loss of heterogeneity and induced differentiation underlies the response to CDK4/6 inhibition
por: Vo, Tuan, et al.
Publicado: (2022)